TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells

Molecular Cancer Research

Volumn 9, Issue 8, 2011, Pages 1042-1053

  Safina, Alfiya ^a   Sotomayor, Paula ^a   Limoge, Michelle ^a   Morrison, Carl ^a   Bakin, Andrei V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYCLOOXYGENASE 2; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN TAB1; PROTEIN TAB2; PROTEIN TAB3; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DESTRUCTION; BONE METASTASIS; BREAST CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CYCLOOXYGENASE 2; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MAP KINASE KINASE KINASES; MATRIX METALLOPROTEINASE 9; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 80051967783     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0196     Document Type: Article

References (73)

1. Lipton A. Future treatment of bone metastases. Clin Cancer Res 2006;12:6305s-63058
2. Muraoka-Cook R.S., Dumont N., Arteaga C.L. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005;11:937s-9343
3. Roberts A.B., Wakefield L.M. The two faces of transforming growth factor {beta} in carcinogenesis. Proc Natl Acad Sci U S A 2003;100:8621-8623 (Pubitemid 36899145)
4. Dunker N., Krieglstein K. Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis. Eur J Biochem 2000;267:6982-6988 (Pubitemid 32009439)
5. Ashcroft G.S., Yang X., Glick A.B., Weinstein M., Letterio J.L., Mizel D.E., et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1999;1:260-266 (Pubitemid 129495775)
6. Yin J.J., Selander K., Chirgwin J.M., Dallas M., Grubbs B.G., Wieser R., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206. (Pubitemid 29053137)
7. Kozlow W., Guise T.A. Breast cancer metastasis to bone: Mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005;10:169-180 (Pubitemid 41031006)
8. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-791
9. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584 (Pubitemid 37280136)
10. Bakin A.V., Tomlinson A.K., Bhowmick N.A., Moses H.L., Arteaga C.L. Phosphatidylinositol 3-kinase function is required for TGFbeta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000;275:36803-36810 (Pubitemid 32002090)
11. Dumont N., Bakin A.V., Arteaga C.L. Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J Biol Chem 2003;278:3275-3285 (Pubitemid 36801240)
12. Bhowmick N.A., Zent R., Ghiassi M., McDonnell M., Moses H.L. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem 2001;276:46707-46713
13. Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Oishi I., Ueno N., et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995;270:2008-2011 (Pubitemid 26097194)
14. Shibuya H., Iwata H., Masuyama N., Gotoh Y., Yamaguchi K., Irie K., et al. Role of TAK1 and TAB1 in BMP signaling in early Xenopus development. EMBO J 1998;17:1019-1028 (Pubitemid 28077656)
15. Sato S., Sanjo H., Takeda K., Ninomiya-Tsuji J., Yamamoto M., Kawai T., et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005;6:1087-1095 (Pubitemid 41541786)
16. Singhirunnusorn P., Suzuki S., Kawasaki N., Saiki I., Sakurai H. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-{beta}-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem 2005;280:7359-7368 (Pubitemid 40341294)
17. Karin M., Greten FR. NF-[kappa]B: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-759 (Pubitemid 41400849)
18. Safina A., Ren M-Q, Vandette E., Bakin A.V. TAK1 is required for TGF-[beta]1-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene 2008;27:1198-1207 (Pubitemid 351294699)
19. Farina A.R., Coppa A., Tiberio A., Tacconelli A., Turco A., Colletta G., et al. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 1998;75:721-730 (Pubitemid 28145819)
20. Suarez-Cuervo C., Merrell M.A., Watson L., Harris K.W., Rosenthal E.L., Vaananen H.K., et al. Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis 2004;21:525-533
21. Safina A., Vandette E., Bakin A.V. ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene 2007;26:2407-2422 (Pubitemid 46597273)
22. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744
23. Chantrain C.F., Shimada H., Jodele S., Groshen S., Ye W., Shalinsky D.R., et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004;64:1675-1686 (Pubitemid 38428689)
24. Ortega N., Behonick D.J., Werb Z. Matrix remodeling during endochondral ossification. Trends Cell Biol 2004;14:86-93. (Pubitemid 38186642)
25. Yoneda T., Michigami T., Yi B., Williams P.J., Niewolna M., Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000;88:2979-2988 (Pubitemid 30413180)
26. Park B.K., Zhang H., Zeng Q., Dai J., Keller E.T., Giordano T., et al. NFkappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007;13:62-69 (Pubitemid 46067387)
27. Gordon A.H., O'Keefe R.J., Schwarz E.M., Rosier R.N., Puzas J.E. Nuclear factor-{kappa}B-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone. Cancer Res 2005;65:3209-3217 (Pubitemid 40524603)
28. Arsura M., Panta G.R., Bilyeu J.D., Cavin L.G., Sovak M.A., Oliver A.A., et al. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: Implications in liver tumor formation. Oncogene 2003;22:412-425 (Pubitemid 36194337)
29. Hoffmann A., Preobrazhenska O., Wodarczyk C., Medler Y., Winkel A., Shahab S., et al. Transforming growth factor-{beta}-activated kinase-1 (TAK1), a MAP3K, interacts with Smad proteins and interferes with osteogenesis in murine mesenchymal progenitors. J Biol Chem 2005;280:27271-27283 (Pubitemid 41040767)
30. Benus G.F.J.D., Wierenga A.T.J., De Gorter D.J.J., Schuringa J.J., Van Bennekum A.M., Drenth-Diephuis L., et al. Inhibition of the transforming growth factor {beta} (TGF{beta}) pathway by interleukin-1{beta} is mediated through TGF{beta}-activated kinase 1 phosphorylation of SMAD3. Mol Biol Cell 2005;16:3501-3510 (Pubitemid 41077064)
31. Sakurai H., Miyoshi H., Toriumi W., Sugita T. Functional interactions of transforming growth factor beta-activated kinase 1 with Ikappa B kinases to stimulate NF-kappa B activation. J Biol Chem 1999;274:10641-10648
32. Bakin A.V., Rinehart C., Tomlinson A.K., Arteaga C.L. p38 mitogen-activated protein kinase is required for TGF{beta}-mediated fibroblastic transdifferentiation and cell migration. J Cell Science 2002;115:3193-3206
33. Arguello F., Furlanetto R.W., Baggs R.B., Graves B.T., Harwell S.E., Cohen H.J., et al. Incidence and distribution of experimental metastases in mutant mice with defective organ microenvironments (genotypes Sl/Sld and W/Wv). Cancer Res 1992;52:2304-2309
34. Sasaki A., Boyce B.F., Story B., Wright K.R., Chapman M., Boyce R., et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995;55:3551-3557
35. Kakonen S-M, Selander K.S., Chirgwin J.M., Yin J.J., Burns S., Rankin W.A., et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002;277:24571-24578 (Pubitemid 34951984)
36. Janssens K., ten Dijke P., Janssens S., Van Hul W. Transforming growth factor-{beta}1 to the bone. Endocr Rev 2005;26:743-774
37. Arguello F., Baggs R.B., Frantz C.N. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988;48:6876-6881 (Pubitemid 19012221)
38. Guise T.A., Yin J.J., Taylor S.D., Kumagai Y., Dallas M., Boyce B.F., et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-1549 (Pubitemid 26327863)
39. Cailleau R., Young R., Olive M., Reeves W.J. Jr. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974;53:661-674
40. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-549 (Pubitemid 36808649)
41. Kang Y., He W., Tulley S., Gupta G.P., Serganova I., Chen C-R, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005;102:13909-13914 (Pubitemid 41377677)
42. Shibuya H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y., Ueno N., et al. TAB1: An activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996;272:1179-1182
43. Takaesu G., Kishida S., Hiyama A., Yamaguchi K., Shibuya H., Irie K., et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 2000;5:649-658
44. Mizukami J., Takaesu G., Akatsuka H., Sakurai H., Ninomiya-Tsuji J., Matsumoto K., et al. Receptor activator of NF-{kappa}B ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 2002;22:992-1000. (Pubitemid 34094837)
45. Ishitani T., Takaesu G., Ninomiya-Tsuji J., Shibuya H., Gaynor R.B., Matsumoto K. Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling. EMBO J 2003;22:6277-6288 (Pubitemid 37522585)
46. Adhikari A., Xu M., Chen Z.J. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 2007;26:3214-3226 (Pubitemid 46763016)
47. Yoneda T., Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005;328:679-687 (Pubitemid 40208305)
48. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998;93:411-422 (Pubitemid 28232085)
49. Lucci A., Krishnamurthy S., Singh B., Bedrosian I., Meric-Bernstam F., Reuben J., et al. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 2009;117:61-68
50. Li Z., Schem C., Shi Y.H., Medina D., Zhang M. Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis. Clin Exp Metastasis 2008;25:389-400. (Pubitemid 351748983)
51. Koulouvaris P., Ly K., Ivashkiv L.B., Bostrom M.P., Nestor B.J., Sculco T.P., et al. Expression profiling reveals alternative macrophage activation and impaired osteogenesis in periprosthetic osteolysis. J Orthop Res 2008;26:106-116
52. Virk M., Lieberman J. Tumor metastasis to bone. Arthritis Res Ther 2007;9:S5.
53. Incorvaia L., Badalamenti G., Rini G., Arcara C., Fricano S., Sferrazza C., et al. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res 2007;27:1519-1525 (Pubitemid 46807231)
54. Himelstein B.P., Asada N., Carlton M.R., Collins M.H. Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol 1998;31:471-474 (Pubitemid 28535913)
55. Lee J., Weber M., Mejia S., Bone E., Watson P., Orr W. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur J Cancer 2001;37:106-113 (Pubitemid 32119367)
56. Weber M.H., Lee J., Orr F.W. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol 2002;20:299-303.
57. Arsura M., FitzGerald M.J., Fausto N., Sonenshein G.E. Nuclear factorkappaB/Rel blocks transforming growth factor beta1-induced apoptosis of murine hepatocyte cell lines. Cell Growth Differ 1997;8:1049-1059 (Pubitemid 27433293)
58. Azuma M., Motegi K., Aota K., Yamashita T., Yoshida H., Sato M. TGF-[beta]1 inhibits NF-[kappa]B activity through induction of I[kappa]B-[alpha] expression in human salivary gland cells: A possible mechanism of growth suppression by TGF-[beta]1. Exp Cell Res 1999;250:213-222 (Pubitemid 29391585)
59. Nagarajan R.P., Chen F., Li W., Vig E., Harrington M.A., Nakshatri H., et al. Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB. Biochem J 2000;348:591-596 (Pubitemid 30410249)
60. Verrecchia F., Tacheau C., Wagner E.F., Mauviel A. A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression. J Biol Chem 2003;278:1585-1593 (Pubitemid 36801388)
61. Bitzer M., Von Gersdorff G., Liang D., Dominguez-Rosales A., Beg A.A., Rojkind M., et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev 2000;14:187-197 (Pubitemid 30070984)
62. Wang W., Huang X.R., Li A.G., Liu F., Li J-H, Truong L.D., et al. Signaling mechanism of TGF-{beta}1 in prevention of renal inflammation: Role of Smad7. J Am Soc Nephrol 2005;16:1371-1383 (Pubitemid 41716521)
63. Deckers M., Van Dinther M., Buijs J., Que I., Lowik C., Van der Pluijm G., et al. The tumor suppressor Smad4 is required for transforming growth factor {beta}-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006;66:2202-2209
64. Sliva D., Rizzo M.T., English D. Phosphatidylinositol 3-kinase and NFkappa B regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 2002;277:3150-3157 (Pubitemid 34953176)
65. Ogata H., Sato H., Takatsuka J., De Luca L.M. Human breast cancer MDA-MB-231 cells fail to express the neurofibromin protein, lack its type I mRNA isoform and show accumulation of P-MAPK and activated Ras. Cancer Lett 2001;172:159-164 (Pubitemid 32889711)
66. Kretzschmar M., Doody J., Timokhina I., Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 1999;13:804-816 (Pubitemid 29169840)
67. Saha D., Datta P.K., Beauchamp R.D. Oncogenic Ras represses transforming growth factor-beta/Smad signaling by degrading tumor suppressor Smad4. J Biol Chem 2001;276:29531-29537
68. Reffey S.B., Wurthner J.U., Parks W.T., Roberts A.B., Duckett C.S. X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling. J Biol Chem 2001;276:26542-26549
69. Yamaguchi K., Nagai S., Ninomiya-Tsuji J., Nishita M., Tamai K., Irie K., et al. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J 1999;18:179-187 (Pubitemid 29005034)
70. Mendoza H., Campbell D.G., Burness K., Hastie J., Ronkina N., Shim J.H., et al. Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. Biochem J 2008;409:711-722 (Pubitemid 351214197)
71. Inagaki M., Omori E., Kim J-Y, Komatsu Y., Scott G., Ray M.K., et al. TAK1-binding protein 1, TAB1, mediates osmotic stress-induced TAK1 activation but is dispensable for TAK1-mediated cytokine signaling. J Biol Chem 2008;283:33080-33086
72. Arnott J.A., Zhang X., Sanjay A., Owen T.A., Smock S.L., Rehman S., et al. Molecular requirements for induction of CTGF expression by TGFbeta1 in primary osteoblasts. Bone 2008;42:871-885
73. Zhang X., Arnott J.A., Rehman S., DeLong W.G., Sanjay A., Safadi F.F., et al. Src is a major signaling component for CTGF induction by TGF-beta1 in osteoblasts. J Cell Physiol 2010;224:691-701.